Research & Development

Opiant signs contract with BARDA to accelerate OPTN003 product development

Opiant Pharmaceuticals has entered into a multi-year contract with potential funding up to a maximum of approximately $4.6m, with the Biomedical Advanced Research and Development Authority (BARDA) to accelerate the development of its lead product candidate OPTN003.

Cancer Genetics, NovellusDx agree to merge

Cancer Genetics and NovellusDx have signed an agreement, under which NovellusDx will merge with a newly formed Israeli subsidiary of Cancer Genetics and shareholders of NovellusDx will receive stock equal to approximately 49% of the equity of Cancer Genetics on a fully diluted basis.

Novo Nordisk to slash 400 jobs in R&D restructuring

Danish pharmaceutical firm Novo Nordisk has unveiled plans to lay off 400 jobs as part of its efforts to transform its approach on research & development (R&D).

Roivant launches biopharmaceutical firm to develop therapeutics for respiratory diseases

Roivant Sciences has launched Respivant Sciences, a biopharmaceutical company focused on improving the lives of patients suffering from serious respiratory diseases.

Pfizer to evaluate Atomwise’s platform to identify drug candidates for three target proteins

Atomwise, a provider of Artificial Intelligence (AI) for drug discovery and design, has entered into an evaluation agreement with Pfizer.

Allergan to buy clinical-stage biotechnology firm Bonti for $195m

Irish drug maker Allergan has agreed to acquire US-based clinical-stage biotech company Bonti in a deal worth more than $195m.

Boehringer Ingelheim buys Austrian firm ViraTherapeutics for €210m

Boehringer Ingelheim has purchased all shares of Austrian biopharmaceutical firm, ViraTherapeutics, in a deal valued at around €210m.

Immunotherapy firm OncoResponse secures $40m series B financing

OncoResponse, an immunotherapy company developing a portfolio of novel antibodies for cancer, has announced the completion of a $40m series B equity financing.

Summit discovers new mechanism antibiotics to combat ESKAPE pathogen targets

Summit Therapeutics, a UK-based clinical-stage drug discovery and development company, claims to have discovered multiple new mechanism antibiotics against novel ESKAPE pathogen targets.